Ct-202
Phase 1
Ct-202 is one of 10 therapeutic programs targeting Triple Negative Breast Cancer (TNBC). It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
12 competitors in Triple Negative Breast Cancer (TNBC)
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
BL-B01D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Paraplatin
AAvyxa
Phase 2
Retlirafusp Alfa
TTang-Du Hospital
Phase 2
Yervoy
Bristol-Myers SquibbPreclinical
Paclitaxcel
SShanghai Jiao Tong University School of Medicine
Phase 2
Ct-202
CContext Therapeutics Inc.
Phase 1
Breakvax
BBreakBio Corp
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Ct-202. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- CContext Therapeutics Inc.